Treatment of gastrointestinal diffuse large B cell lymphoma in China: A 10-year retrospective study of 114 cases

Annals of Hematology

Volumn 91, Issue 11, 2012, Pages 1721-1729

  Li, Xiaoyang ^a   Shen, Weina ^a   Cao, Junning ^b   Wang, Jianmin ^c   Chen, Fangyuan ^d   Wang, Chun ^e   Zou, Shanhua ^f   Shen, Boyong ^a   Zhao, Ren ^a   Li, Junmin ^a   Shen, Zhixiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^f ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Gastrointestinal DLBCL; Overall survival; Predict prognosis factor; Rituximab; Surgery resection

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHINA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTESTINE LYMPHOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STOMACH LYMPHOMA; SURVIVAL PREDICTION; SURVIVAL RATE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINCRISTINE; YOUNG ADULT;

EID: 84867335995     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1507-1     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward EM, Thun MJ (2008) Cancer facts and figures. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed 19 Jun 2008.
2. Xiao-long JI, Ming-shi SHEN (1999) Extranodal lymphoma in China: an analysis of 943 cases. Chin J Canc 18(5):570-572
3. Freeman C, Berg JW, Cutler SJ (1972) Occurrence and prognosis of extranodal lymphomas. Cancer 29:252-260
4. Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rübe C et al (2001) Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol 19:3861-3873
5. Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, Dimopoulos M, Tsatalas C, Xiros N, Economopoulos T et al (2006) Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma 47:2140-2146
6. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116(12):2040-2045
7. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD et al (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23 (22):5027-5033
8. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127
9. Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z (2012) Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Ann Hematol 91(6):837-845
10. Binn M, Ruskoné-Fourmestraux A, Lepage E, Haioun C, Delmer A, Aegerter P, Lavergne A, Guettier C, Delchier JC (2003) Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma. Ann Oncol 14(12):1751-1757
11. Huang J, Jiang W, Xu R, Huang H, Lv Y, Xia Z, Sun X, Guan Z, Lin T, Li Z (2010) Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors. BMC Cancer 10:358
12. DAmore F, Christensen BE, Brincker H, Pedersen NT, Thorling K, Hastrup J (1991) Clinico-pathological features and prognostic factors in extranodal non-Hodgkin's lymphomas. Eur J Cancer 27:1201-1208
13. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244
14. Aisenberg AC (1995) Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 13:2656-2675
15. Zucca R, Conconi A, Roggero R (2000) Non-gastric MALT lymphoma: a survey of 369 European patients -The International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 11:99
16. Herrmann R, Panahon AM, Barcos MP, Walsh D, Stutzman L (1980) Gastrointestinal involvement in non-Hodgkin's lymphoma. Cancer 46:215-222
17. Avilés A, Nambo MJ, Neri N, Huerta-Guzmán J, Cuadra I, Alvarado I, Castañeda C, Fernández R, González M (2004) The role of surgery in primary gastric lymphoma: results of a controlled clinical trial. Ann Surg 240(1):44-50
18. Tanaka T, Shimada K, Yamamoto K, Hirooka Y, Niwa Y, Sugiura I, Kitamura K, Kosugi H, Kinoshita T, Goto H, Nakamura S (2012) Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan. Ann Hematol 91(3):383-390
19. Aviles A, Castaneda C, Cleto S, Neri N, Huerta-Guzman J, Gonzalez M, Nambo MJ (2009) Rituximab and chemotherapy in primary gastric lymphoma. Cancer Biother Radiopharm 24(1):25-28
20. Gutiérrez-García G, Colomo L, Villamor N, Arenillas L, Martínez A, Cardesa T, García-Herrera A, Setoain X, Rodríguez S, Ghita G, Abrisqueta P, Giné E et al (2010) Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large Bcell lymphoma in the rituximab era. Leuk Lymphoma 51(7):1225-1232
21. Witzens-Harig M, Reiz M, Heiß C, Benner A, Hensel M, Neben K, Dreger P, Kraemer A, Anthony DHo (2009) Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial. Ann Hematol 88(1):51-57
22. Huang BT, Zeng QC, Yu J, Xiao Z, Li BS, Zhang CL, Ji HB (2012) How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience. J Cancer Res Clin Oncol 138(1):125-132
23. Morton JE, Leyland MJ, Vaughan Hudson G, Vaughan Hudson B, Anderson L, Bennett MH, MacLennan KA (1993) Primary gastrointestinal non-Hodgkin's lymphoma: a review of 175 British National Lymphoma Investigation cases. Br J Cancer 67:776-782
24. Salles G, Herbrecht R, Tilly H, Berger F, Brousse N, Gisselbrecht C, Coiffier B (1991) Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d'Etude des Lymphomes Aggressifs. Am J Med 90:77-84
25. Willich NA, Reinartz G, Horst EJ, Delker G, Reers B, Hiddemann W, Tiemann M, Parwaresch R, Grothaus-Pinke B, Kocik J, Koch P (1999) Therapeutic management of stage I-II high grade primary gastric lymphoma. Oncology 56:274-281
26. Xia ZG, Xu ZZ, Zhao WL, Zhao SQ, Ding F, Chen Y, Chen QS, Zheng Y, Zhu Q, Hu JP, Shen ZX, Li JM (2010) The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or RCHOP treatment. Ann Hematol 89(2):171-177
27. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyas F, Gaulard P (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87:265-272
28. Horning SJ, Weller E, Kim K, Earle JD, O'Connell MJ, Habermann TM, Glick JH (2004) Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22(15):3032-3038
29. Ang MK, Hee SW, Quek R, Yap SP, Loong S, Tan L, Tao M, Lim ST (2009) Presence of a high-grade component in gastric mucosaassociated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis. Ann Hematol 88(5):417-424
30. Mok TS, Steinberg J, Chan AT, Yeo WM, Hui P, Leung TW, Johnson P (1998) Application of the international prognostic index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma. Cancer 82 (12):2439-2448
31. Cortelazzo S, Rossi A, Roggero F, Oldani E, Zucca E, Tondini C, Ambrosetti A, Pasini F, Pinotti G, Bertini M, Vitolo U, Busetto M et al (1999) Stage-modified International Prognostic Index effectively predicts outcome of localized primary gastric diffuse large cell lymphoma. Ann Oncol 10:1433-1440
32. Cortelazzo S, Rossi A, Oldani E, Motta T, Giardini R, Zinzani PL, Zucca E, Gomez H, Ferreri AJ, Pinotti G, Chini C, Devizzi L et al (2002) The Modified International Prognostic Index can predict the outcome of localized intestinal lymphoma of both extranodal marginal B-cell and diffuse large B-cell lymphoma. Br J Haematol 118:218-228